{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:31:18Z","timestamp":1792215078697,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012665","name":"institute for clinical evaluative sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"ontario ministry of health and long-term care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010564","name":"academic medical organization of southwestern ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008093","name":"schulich school of medicine and dentistry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004381","name":"western university","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008958","name":"lawson health research institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"canadian institutes of health research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"heart and stroke foundation of canada","doi-asserted-by":"publisher","award":["G-18-0022147"],"award-info":[{"award-number":["G-18-0022147"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of severe (S-HTG) and very severe hypertriglyceridemia (VS-HTG) among Canadians is unknown. This study aimed to determine the incidence, characteristics, predictors and care patterns for individuals with VS-HTG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using linked administrative healthcare databases, a population-based cohort study of Ontario adults was conducted to determine incidence of new onset S-HTG (serum triglycerides (TG) &gt;\u200910\u201320\u2009mmol\/L) and VS-HTG (TG\u2009&gt;\u200920\u2009mmol\/L) between 2010 and 2015. Socio-demographic and clinical characteristics of those with VS-HTG were compared to those who had no measured TG value &gt;\u20093\u2009mmol\/L. Univariable and multivariable logistic regression were used to determine predictors for VS-HTG. Healthcare patterns were evaluated for 2 years following first incidence of TG &gt;\u200920\u2009mmol\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incidence of S-HTG and VS-HTG in Ontario was 0.16 and 0.027% among 10,766,770 adults \u226518\u2009years and 0.25 and 0.041% among 7,040,865 adults with at least one measured TG, respectively. Predictors of VS-HTG included younger age [odds ratios (OR) 0.64\/decade, 95% confidence intervals (CI) 0.62\u20130.66], male sex (OR 3.83; 95% CI 3.5\u20134.1), diabetes (OR 5.38; 95% CI 4.93\u20135.88), hypertension (OR 1.69; 95% CI 1.54\u20131.86), chronic liver disease (OR 1.71; 95% CI 1.48\u20131.97), alcohol abuse (OR 2.47; 95% CI 1.90\u20133.19), obesity (OR 1.49; 95% CI 1.13\u20131.98), and chronic kidney disease (OR 1.39; 95% CI 1.19\u20131.63).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 5-year incidence of S-HTG and VS-HTG in Canadian adults was 1 in 400 and 1 in 2500, respectively. Males, those with diabetes, obese individuals and those with alcohol abuse are at highest risk for VS-HTG and may benefit from increased surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-021-01517-6","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T16:03:42Z","timestamp":1630685022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9461-9036","authenticated-orcid":false,"given":"Amanda J.","family":"Berberich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Ou\u00e9draogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salimah Z.","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"9","key":"1517_CR1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1210\/jc.2011-3213","volume":"97","author":"L Berglund","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969\u201389.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1517_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/2013.jamainternmed.477","volume":"173","author":"MJ Murphy","year":"2013","unstructured":"Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013;173(2):162\u20134.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"1517_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1503\/cmaj.060963","volume":"176","author":"G Yuan","year":"2007","unstructured":"Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113\u201320.","journal-title":"CMAJ"},{"issue":"12","key":"1517_CR4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","volume":"176","author":"SB Pedersen","year":"2016","unstructured":"Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176(12):1834\u201342.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1517_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MOL.0000000000000710","volume":"31","author":"A Wolska","year":"2020","unstructured":"Wolska A, Yang ZH, Remaley AT. Hypertriglyceridemia: new approaches in management and treatment. Curr Opin Lipidol. 2020;31(6):331\u20139.","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"1517_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","volume":"11","author":"AJ Brahm","year":"2015","unstructured":"Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352\u201362.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1517_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.7326\/L17-0182","volume":"167","author":"P Stahel","year":"2017","unstructured":"Stahel P, Xiao C, Hegele RA, Lewis GF. Polygenic risk for hypertriglyceridemia can mimic a major monogenic mutation. Ann Intern Med. 2017;167(5):360\u20131.","journal-title":"Ann Intern Med"},{"key":"1517_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","volume":"283","author":"M Paquette","year":"2019","unstructured":"Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis. 2019;283:137\u201342.","journal-title":"Atherosclerosis"},{"issue":"8","key":"1517_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1517_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","volume":"13","author":"JS Dron","year":"2019","unstructured":"Dron JS, Wang J, Cao H, McIntyre AD, Iacocca MA, Menard JR, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol. 2019;13(1):80\u20138.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1517_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1194\/jlr.R009720","volume":"52","author":"CT Johansen","year":"2011","unstructured":"Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011;52(2):189\u2013206.","journal-title":"J Lipid Res"},{"issue":"9","key":"1517_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.7326\/M19-0203","volume":"170","author":"A Chait","year":"2019","unstructured":"Chait A, Eckel RH. The Chylomicronemia syndrome is Most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019;170(9):626\u201334.","journal-title":"Ann Intern Med"},{"issue":"10","key":"1517_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMcp070061","volume":"357","author":"JD Brunzell","year":"2007","unstructured":"Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357(10):1009\u201317.","journal-title":"N Engl J Med"},{"issue":"1","key":"1517_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12944-017-0511-9","volume":"16","author":"K Retterstol","year":"2017","unstructured":"Retterstol K, Narverud I, Selmer R, Berge KE, Osnes IV, Ulven SM, et al. Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics. Lipids Health Dis. 2017;16(1):115.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"1517_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archinternmed.2008.599","volume":"169","author":"ES Ford","year":"2009","unstructured":"Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169(6):572\u20138.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1517_CR16","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/js.2019-00129","volume":"3","author":"MI Esparza","year":"2019","unstructured":"Esparza MI, Li X, Adams-Huet B, Vasandani C, Vora A, Das SR, et al. Very severe hypertriglyceridemia in a large US County health care system: associated conditions and management. J Endocr Soc. 2019;3(8):1595\u2013607.","journal-title":"J Endocr Soc"},{"issue":"6","key":"1517_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","volume":"107","author":"JB Christian","year":"2011","unstructured":"Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2,000 mg\/dl) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107(6):891\u20137.","journal-title":"Am J Cardiol"},{"key":"1517_CR18","unstructured":"International statistical classification of diseases and related health problems, 10th revision, 5th edition. World Health Organization; 2016. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/246208."},{"key":"1517_CR19","unstructured":"Canadian Classification Of Health Interventions 2015. Available from: https:\/\/www.cihi.ca\/sites\/default\/files\/cci_volume_four_2015_en_0.pdf. Accessed 5 Mar 2020."},{"issue":"1","key":"1517_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12913-018-3148-0","volume":"18","author":"LL Lipscombe","year":"2018","unstructured":"Lipscombe LL, Hwee J, Webster L, Shah BR, Booth GL, Tu K. Identifying diabetes cases from administrative data: a population-based validation study. BMC Health Serv Res. 2018;18(1):316.","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"1517_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1503\/cmaj.071283","volume":"178","author":"K Tu","year":"2008","unstructured":"Tu K, Chen Z, Lipscombe LL. Canadian hypertension education program outcomes research T. prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ. 2008;178(11):1429\u201335.","journal-title":"CMAJ"},{"issue":"4","key":"1517_CR22","doi-asserted-by":"publisher","first-page":"E624","DOI":"10.9778\/cmajo.20190065","volume":"7","author":"C Iskander","year":"2019","unstructured":"Iskander C, McArthur E, Nash DM, Gandhi-Banga S, Weir MA, Muanda FT, et al. Identifying Ontario geographic regions to assess adults who present to hospital with laboratory-defined conditions: a descriptive study. CMAJ Open. 2019;7(4):E624\u2013E9.","journal-title":"CMAJ Open"},{"key":"1517_CR23","unstructured":"Ontario Lab Data and Your EMR. eHealth Ontario; 2016.  Available from: https:\/\/ehealthontario.on.ca\/files\/public\/support\/OLIS_EMR_ProviderGuide_EN.pdf. Accessed 5 Mar 2020."},{"issue":"6","key":"1517_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat. 2009;38(6):1228\u201334.","journal-title":"Commun Stat"},{"issue":"10","key":"1517_CR25","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.","journal-title":"PLoS Med"},{"issue":"8","key":"1517_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1517_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4158\/EP-2018-0599","volume":"25","author":"M Morkos","year":"2019","unstructured":"Morkos M, Amblee A, Henriquez A, Basu S, Fogelfeld L. External validation of a predictive model for acute pancreatitis risk in patients with severe hypertriglyceridemia. Endocr Pract. 2019;25(8):817\u201323.","journal-title":"Endocr Pract"},{"key":"1517_CR28","unstructured":"Canadian Health Measures Survey. 2017. Available from: https:\/\/www150.statcan.gc.ca\/n1\/pub\/11-627-m\/11-627-m2018033-eng.htm Accessed 28 July 2020.."},{"key":"1517_CR29","volume-title":"Diabetes in Canada","author":"D Canada","year":"2021","unstructured":"Canada D. Diabetes in Canada; 2021."},{"key":"1517_CR30","unstructured":"Immigration and Ethnocultural Diversity Highlight Tables. 2016. Available from: https:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/dp-pd\/hlt-fst\/imm\/Table.cfm?Lang=E&T=41&Geo=00&SP=1&vismin=2&age=1&sex=1. Accessed 28 July 2020."},{"key":"1517_CR31","unstructured":"Overweight and obesity - BMI statistics. 2019. Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Overweight_and_obesity_-_BMI_statistics. Accessed 28 July 2020."},{"key":"1517_CR32","unstructured":"Obesity and overweight. 2021. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 28 July 2020."},{"issue":"8","key":"1517_CR33","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/archinte.1990.00040031653012","volume":"150","author":"L Bookstein","year":"1990","unstructured":"Bookstein L, Gidding SS, Donovan M, Smith FA. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the National Cholesterol Education Program guidelines. Arch Intern Med. 1990;150(8):1653\u20137.","journal-title":"Arch Intern Med"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01517-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T16:04:32Z","timestamp":1630685072000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01517-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01517-6","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ICES is a prescribed entity under section 45 of Ontario\u2019s Personal Health Information Protection Act. Section 45 authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects conducted under section 45, by definition, do not require review by a Research Ethics Board. This project was conducted under section 45, and approved by ICES\u2019 Privacy and Compliance Office.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KC received a research award that was sponsored in part by Astra Zeneca. She has attended Merck sponsored medical conferences. She has received honoraria for delivering Certified Medical Education talks from Sutherland Global Services Canada ULC, the Toronto Ontario Knowledge Translation Working Group, and the Canadian Medical and Surgical Knowledge Translation Research Group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}